NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects through ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Barrett told his grandma Honey, also known as Jill Lee, about the idea.

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...

Oct. 7, 2024 — Fratricide-resistant CD7 CAR-T therapy by NUS proves effective ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

UIC researchers have redesigned asparaginase, a key leukemia treatment, to reduce severe side effects like liver damage and ...